Sight Sciences, Inc.
SGHTNasdaq
$5.03
↓ -3.3%Jul 17 close · end-of-day
Price
1Y↑ +43.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$271.3M
Enterprise Value
$226.9M
P/E
—
P/S
3.4
P/B
5.0
EV/EBITDA
—
PEG
—
FCF Yield
-9.4%
Dividend Yield
—
Revenue (TTM)
$79.6M
Net Income (TTM)
-$37.3M
Free Cash Flow (TTM)
-$25.4M
Gross Margin
86.2%
Operating Margin
-44.8%
Net Margin
-46.8%
ROE
-69.1%
ROIC
-297.3%
Debt / Equity
0.8
Net Cash
$44.4M
Return 1Y
+42.1%
Company profile
Sight Sciences, Inc. engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. Its products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
- CEO
- Paul Badawi
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 210
- Headquarters
- California
- Website
- sightsciences.com
Management & directors
- Badawi DavidChief Technology Officer
- Hayden Jeremy B.Chief Legal Officer
- Bauerlein AlisonChief Operating Officer
- Rodberg JamesChief Financial Officer
- Badawi PaulPresident and CEO
- Taylor BrentonEVP, Operations & R&D
- Link MatthewChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
SGHT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$19.7M↑ +12.5%
Diluted EPS-$0.24↓ -14.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $27.6M | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M |
| Gross profit | $18.4M | $40.3M | $59.0M | $69.2M | $68.3M | $66.7M |
| Operating income | -$32.2M | -$51.5M | -$84.0M | -$57.3M | -$50.5M | -$37.1M |
| Net income | -$34.7M | -$63.0M | -$86.2M | -$55.5M | -$51.5M | -$38.4M |
| Diluted EPS | — | -$2.36 | -$1.80 | -$1.14 | -$1.03 | -$0.74 |
| Operating cash flow | -$32.2M | -$52.5M | -$76.0M | -$47.2M | -$22.4M | -$29.7M |
| Free cash flow | -$33.1M | -$53.4M | -$76.9M | -$48.0M | -$22.7M | -$29.9M |
| Gross margin | 66.7% | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Operating margin | -116.5% | -105.2% | -117.7% | -70.7% | -63.3% | -48.0% |
| Net margin | -125.5% | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.4M | $20.2M | $19.1M | $17.5M | $19.6M | $19.9M | $20.4M | $19.7M |
| Gross profit | $18.3M | $16.9M | $16.6M | $15.1M | $16.6M | $17.2M | $17.8M | $17.0M |
| Operating income | -$12.7M | -$11.2M | -$11.9M | -$13.9M | -$11.7M | -$7.9M | -$3.7M | -$12.4M |
| Net income | -$12.3M | -$11.1M | -$11.8M | -$14.2M | -$11.9M | -$8.2M | -$4.2M | -$13.0M |
| Diluted EPS | -$0.25 | -$0.22 | -$0.23 | -$0.28 | -$0.23 | -$0.16 | -$0.07 | -$0.24 |
| Operating cash flow | -$9.5M | $362,000.00 | -$3.5M | -$11.6M | -$7.5M | -$8.7M | -$1.8M | -$7.0M |
| Free cash flow | -$9.5M | $311,000.00 | -$3.6M | -$11.6M | -$7.8M | -$8.9M | -$2.0M | -$7.1M |
| Gross margin | 85.8% | 83.9% | 86.8% | 86.2% | 84.8% | 86.4% | 87.3% | 86.2% |
| Operating margin | -59.2% | -55.7% | -62.5% | -79.2% | -59.6% | -39.7% | -18.0% | -63.0% |
| Net margin | -57.7% | -54.9% | -62.1% | -80.8% | -61.0% | -41.0% | -20.4% | -65.9% |
Company news
May 7, 2026
May 6, 2026
- 74d agoSight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimatesfinance.yahoo.com
- 74d agoSight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimatesfinance.yahoo.com
- 74d agoSight Sciences (SGHT) Q1 2026 Earnings Transcriptfool.com
- 75d agoSight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidancefinance.yahoo.com
Apr 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | HAYDEN JEREMY B.· Chief Legal Officer | Sale | 12,733 | $5.51 | $70,133.36 | filing |
| 2026-07-06 | Badawi David· Chief Technology Officer | Sale | 7,418 | $5.51 | $40,858.34 | filing |
| 2026-07-02 | Bauerlein Alison· Chief Operating Officer | Sale | 24,184 | $5.36 | $129,626.24 | filing |
| 2026-07-02 | Rodberg James· Chief Financial Officer | Sale | 6,902 | $5.36 | $36,994.72 | filing |
| 2026-07-01 | Badawi Paul· President and CEO | Sale | 28,684 | $5.42 | $155,467.28 | filing |
| 2026-07-01 | Taylor Brenton· EVP, Operations & R&D | Sale | 2,829 | $5.42 | $15,333.18 | filing |
| 2026-06-10 | Encrantz Staffan | Buy | 14,100 | $4.88 | $68,793.90 | filing |
| 2026-06-04 | Fountain Tamara | Award | 28,261 | $0.00 | $0.00 | filing |
| 2026-06-04 | Encrantz Staffan | Award | 28,261 | $0.00 | $0.00 | filing |
| 2026-06-04 | Burbach Gerhard F | Award | 28,261 | $0.00 | $0.00 | filing |
| 2026-06-04 | Zurbay Donald | Award | 28,261 | $0.00 | $0.00 | filing |
| 2026-06-04 | Mazzacco Catherine | Award | 28,261 | $0.00 | $0.00 | filing |
| 2026-05-18 | Bauerlein Alison· Chief Operating Officer | Sale | 12,728 | $5.12 | $65,167.36 | filing |
| 2026-04-06 | HAYDEN JEREMY B.· Chief Legal Officer | Sale | 13,761 | $3.55 | $48,851.55 | filing |
| 2026-04-06 | Rodberg James· Chief Financial Officer | Sale | 7,231 | $3.55 | $25,670.05 | filing |
| 2026-04-02 | Bauerlein Alison· Chief Operating Officer | Sale | 25,874 | $3.48 | $90,041.52 | filing |
| 2026-04-02 | Badawi David· Chief Technology Officer | Sale | 8,168 | $3.48 | $28,424.64 | filing |
| 2026-04-01 | Badawi Paul· President and CEO | Sale | 29,244 | $3.70 | $108,202.80 | filing |
| 2026-04-01 | Taylor Brenton· EVP, Operations & R&D | Sale | 2,869 | $3.70 | $10,615.30 | filing |
| 2026-02-19 | Badawi David· Chief Technology Officer | Option exercise | 21,270 | $0.23 | $4,892.10 | filing |
| 2026-02-03 | Rodberg James· Chief Financial Officer | Award | 86,940 | $0.00 | $0.00 | filing |
| 2026-02-03 | Taylor Brenton· EVP, Operations & R&D | Award | 100,464 | $0.00 | $0.00 | filing |
| 2026-02-03 | Badawi David· Chief Technology Officer | Award | 64,915 | $0.00 | $0.00 | filing |
| 2026-02-03 | HAYDEN JEREMY B.· Chief Legal Officer | Award | 115,920 | $0.00 | $0.00 | filing |
| 2026-02-03 | Bauerlein Alison· Chief Operating Officer | Award | 127,512 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.